Evaluation of Circulating Tumor DNA Levels as a Predictive Marker ...

Description. This phase II trial evaluates circulating tumor deoxyribonucleic acid (ctDNA) levels as a predictive marker on switching treatment earlier in ...

Evaluation of circulating tumor DNA as a biomarker for ...

The detection and analysis of ctDNA can provide genomic information on the size and development of tumor; therefore, it is considered as an emerging and ...

Early evaluation of circulating tumor DNA as marker of therapeutic ...

We assessed the potential role of serial circulating tumor DNA (ctDNA) as a biomarker to monitor treatment response to primary systemic therapy (PST) in breast ...

Evaluation of circulating tumor DNA as a prognostic biomarker for ...

The ctDNA has the potential as a specific survival predictive marker for metastatic PAC patients ... levels and mutations in ≥ 3 driver ...

Evaluation of circulating tumor DNA as a prognostic biomarker for ...

Recent research has shown that ctDNA might be used as a biomarker in various malignancies. In cancer patients, the ctDNA levels rise in response to various ...

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic ...

The initial concentration of ctDNA appeared as a prognostic marker in patients with metastatic colorectal cancer. Furthermore, an early and deep decrease of ...

Prospective assessment of circulating tumor DNA in patients with ...

Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using multiplex PCR- ...

Changes in circulating tumor DNA and outcomes in solid tumors ...

There is a need to validate dynamic markers that provide early and reliable insights about disease response. The predictive role of circulating tumor DNA (ctDNA) ...

Circulating tumor DNA as a potential prognostic and predictive ...

Next, we analyzed the ctDNA abundance with the max VAF of detected mutations, and evaluated the relation of ctDNA abundance, tumor size of primary cancer and ...

circulating tumor DNA (ctDNA) - Know Your Biomarker

ctDNA can be measured in blood to identify the presence of residual cancer cells after surgery or to monitor for cancer recurrence after successful treatment.

Analytical evaluation of circulating tumor DNA sequencing assays

The test assays were generally comparable or superior to the benchmark assay, demonstrating high analytical sensitivity. Variations in ...

Using Circulating Tumor DNA in Colorectal Cancer: Current and ...

Emerging data demonstrate that aside from a prognostic marker, ctDNA may also be a predictive biomarker of response to adjuvant therapy.

Circulating tumor DNA as prognostic markers of relapsed breast ...

ctDNA can be used as an early potential postoperative prognosis biomarker in breast cancer, and also as a reference index to evaluate the therapeutic effect at ...

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic ...

The change in ctDNA concentration was evaluated between C0 and C2 as an early predictive marker of treatment efficacy [better objective response ...

Circulating tumor DNA clearance predicts prognosis across ...

Circulating tumor DNA (ctDNA), validated as a tool for mutation detection in lung cancer, could reflect dynamic molecular changes. We evaluated the utility of ...

Clinical Validity of Circulating Tumor DNA as Prognostic and ... - MDPI

Circulating tumor DNA (ctDNA) is a promising liquid biopsy (LB) marker to support clinical decisions in precision medicine. For implementation into routine ...

Circulating Tumor DNA and Survival in Metastatic Breast Cancer

Conclusions and Relevance In this systematic review and meta-analysis, detection of specific genomic alterations in ctDNA was associated with ...

Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers

The use of ctDNA as a prognostic and predictive marker in patients with gastric cancer is limited; an ongoing prospective observational study ( ...

Integrating Imaging and Circulating Tumor DNA Features for ... - MDPI

ctDNA-based biomarkers represent less invasive approaches to evaluating tumor response and patient survival and, therefore, can be measured repeatedly via ...

Monitoring of Early Changes of Circulating Tumor DNA in ... - Frontiers

Accordingly, there is an unmet need to identify predictive markers allowing to identify non-responders to avoid its adverse effects. We ...